• Chronic heart failure with reduced ejection fraction (HFrEF).
• Sacubitril: Neprilysin inhibitor, increases levels of natriuretic peptides. • Valsartan: Angiotensin II receptor blocker (ARB), reduces vasoconstriction and aldosterone secretion.
• Absorption: Rapidly absorbed, peak plasma concentrations in 1.5-2 hours. • Metabolism: Sacubitril metabolized to active metabolite; valsartan largely unchanged. • Elimination: Sacubitril metabolite half-life ~11 hours; valsartan half-life ~9.9 hours.
• 50-200 mg twice daily, based on patient tolerance and prior ACE inhibitor/ARB use.
Alu-alu strip of 10*10s